Bioanalytical Systems, Inc. to Present at the 10th Annual Noble Financial
Capital Markets Equity Conference Wednesday, January 22, 2014 at 10:00 a.m.
Noble Financial Capital Markets Equity Conference 2014
WEST LAFAYETTE, Ind. -- January 14, 2014
Bioanalytical Systems, Inc. (NASDAQ:BASI) announced today that it will make a
presentation at the Tenth Annual Noble Financial Capital Markets Equity
Conference on Wednesday, January 22, 2014 at 10:00 a.m. EST in Room 1 at the
Club Med in Sandpiper Bay, Florida.
You can access a live audio high-definition video of BASi's presentation and
presentation materials online from the Investors tab at www.BASinc.com or at
www.Noblefcm.com. The webcast requires the installation of Microsoft
Silverlight viewer and will be available for replay at BASi's website for 90
days after the presentation. Please register for the webcast at least 10
minutes before the presentation begins.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development
companies and medical research organizations. The company focuses on
developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit www.BASinc.com for more
About Noble Financial
Noble Financial Capital Markets was established in 1984; 2014 marks its 30th
Anniversary. Noble Financial is an equity research driven, full-service,
investment banking boutique focused on life sciences, technology and media,
emerging growth, companies. The company has offices in Boston, Los Angeles,
and Boca Raton, FL. In addition to non-deal road shows and sector-specific
conferences throughout the year, Noble Financial hosts its large format annual
equity conference in January in South Florida featuring 120-150 presenting
companies from across North America and total attendance of close to 600. For
more information: www.noblefcm.com.
This release may contain forward-looking statements that are subject to risks
and uncertainties including, but not limited to, risks and uncertainties
related to changes in the market and demand for our products and services, the
development, marketing and sales of products and services, changes in
technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company's filings with the Securities and
Bioanalytical Systems, Inc.
President, CEO and CFO
Press spacebar to pause and continue. Press esc to stop.